Virax Biolabs Forms New Distribution Agreement with Tebubio
In an exciting development for the biotechnology sector, Virax Biolabs Group Limited (NASDAQ: VRAX), a forward-thinking company specializing in immune response detection and viral disease diagnosis, has announced its new distribution agreement with the French company Tebubio. This collaboration aims to enhance the availability of Virax's ImmuneSelect Research Use portfolio within the European Union and neighboring countries.
Expanding Access to ImmuneSelect Products
Highlighting the importance of this partnership, James Foster, the CEO of Virax Biolabs, expressed enthusiasm regarding the agreement with Tebubio, emphasizing their essential role in broadening the reach of ImmuneSelect products to life science institutions across Europe. The expansion is a testament to Virax's ongoing commitment to advancing immune profiling technologies and addressing the growing need for insights into immune health through their flagship product, ImmuneSelect.
Strategic Significance for Both Companies
Romain Cordonnier-Goulay, the Chief Scientific Officer of Tebubio, remarked on the significance of this collaboration, noting it reflects Tebubio's dedication to promoting innovative diagnostic tools. With comprehensive distribution networks throughout Europe, Tebubio is well-positioned to facilitate greater access to ImmuneSelect amongst researchers, fulfilling essential research needs in the process.
Understanding ImmuneSelect
ImmuneSelect represents a significant arm of Virax's offerings, focusing on the realm of adaptive immunity. The products within this portfolio are intended solely for research and investigational use, not as diagnostic tools. This range includes specialized peptide pools targeting pathogens, optimized for T-cell stimulation. Current product offerings encompass various pools designed for well-known viruses like SARS-CoV-2, Lyme Disease, and Epstein-Barr Virus (EBV), with ongoing updates to the portfolio to reflect emerging research needs.
Applications and Benefits of ImmuneSelect
ImmuneSelect's recombinant antibodies focus on cytokines and biomarkers, providing researchers with versatile options for applications such as Flow Cytometry and ELISA. With a user-friendly design and compatibility with standard lab equipment, the ImmuneSelect series stands out as an affordable and effective tool for laboratories seeking to enhance their research outputs.
About Virax Biolabs Group Limited
Established as a trailblazer in innovative biotechnology, Virax Biolabs Group Limited is committed to pioneering solutions that enhance the detection of immune responses in viral diseases. The company's advancements in T-cell-based testing technologies are geared toward building an immunology profiling platform, critical for diagnosing conditions such as Long COVID and other post-viral syndromes linked to immune dysfunction.
About Tebubio
Tebubio operates with the mission of supporting life sciences research across Europe. By offering a comprehensive range of solutions tailored for life sciences and biotechnology researchers, Tebubio contributes fundamentally to advancing scientific projects. Their strategically located offices across the region ensure that researchers can access the necessary resources promptly.
Frequently Asked Questions
What is the purpose of the agreement between Virax Biolabs and Tebubio?
The agreement aims to expand the distribution of ImmuneSelect products throughout Europe, enhancing access for research institutions.
What does ImmuneSelect offer?
ImmuneSelect includes research products focused on adaptive immunity, like peptide pools for T-cell stimulation and recombinant antibodies.
What significance does this partnership hold for Virax Biolabs?
It strengthens Virax's efforts in immune profiling and demonstrates their commitment to making essential research tools more accessible.
Who can benefit from ImmuneSelect?
Life science researchers across Europe can benefit, as the products are tailored for research and investigational use only.
What is the mission of Tebubio?
Tebubio aims to facilitate life sciences research by providing innovative solutions to advance scientific projects effectively.
